H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

The consultation meetings discuss innovative, early-stage investigational products and ... for innovative pharmaceutical products, medical devices and regenerative medicines.

RenovoRx (NASDAQ: RNXT) , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath(R), a novel, FDA-cleare ...

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

Many consumer devices undergo the FDA clearance process, such as LED masks and fitness trackers that have features like ...

Dry Eye Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future grow ...